Literature DB >> 22337286

Longitudinal and parallel monitoring of neuroinflammation and neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease.

Serge Maia1, Nicolas Arlicot, Emilie Vierron, Sylvie Bodard, Jackie Vergote, Denis Guilloteau, Sylvie Chalon.   

Abstract

As neuroinflammatory processes are involved in the pathogenesis of Parkinson's disease (PD), we achieved the longitudinal evaluation of them in parallel with the modifications of dopaminergic function at several time-points after 6-hydroxydopamine (6-OHDA) lesion in the rat mimicking an early stage of PD. After unilateral intrastriatal 6-OHDA administration, we quantified the temporal evolution of the 18 kDa translocator protein (TSPO), TH-immunoreactivity and dopamine transporters in the striatum and substantia nigra pars compacta (SNc) from 3- to 56-days postlesion (dpl). Increased binding of TSPO ligands used, i.e., [(3)H]PK11195 and [(125)I]CLINDE, was observed in the lesioned striatum at 3, 7, and 14 dpl, followed by a progressive return to the basal level at 56 dpl. The binding profile in the SNc showed progressive binding beginning at 3 dpl, peaking at 14 dpl, and progressively decreasing until 56 dpl. In this model, the neuroinflammatory and neurodegenerative processes occurred concomitantly. The transitory occurrence of microglial activation could be involved in the lasting installation of dopaminergic neuron loss.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22337286     DOI: 10.1002/syn.21543

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  18 in total

1.  [11C]PBR28 PET imaging is sensitive to neuroinflammation in the aged rat.

Authors:  Matthew D Walker; Katherine Dinelle; Rick Kornelsen; Nathan V Lee; Qing Miao; Mike Adam; Christine Takhar; Edwin Mak; Michael Schulzer; Matthew J Farrer; Vesna Sossi
Journal:  J Cereb Blood Flow Metab       Date:  2015-04-01       Impact factor: 6.200

Review 2.  Exploring mitochondrial cholesterol signalling for therapeutic intervention in neurological conditions.

Authors:  Radha Desai; Michelangelo Campanella
Journal:  Br J Pharmacol       Date:  2019-08-09       Impact factor: 8.739

3.  Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats.

Authors:  Christopher J Barnum; Xi Chen; Jaegwon Chung; Jianjun Chang; Martha Williams; Nelly Grigoryan; Raymond J Tesi; Malú G Tansey
Journal:  J Parkinsons Dis       Date:  2014       Impact factor: 5.568

Review 4.  Microglial phenotypes in Parkinson's disease and animal models of the disease.

Authors:  Valerie Joers; Malú G Tansey; Giovanna Mulas; Anna R Carta
Journal:  Prog Neurobiol       Date:  2016-04-20       Impact factor: 11.685

5.  Neurotoxin-Induced Catecholaminergic Loss in the Colonic Myenteric Plexus of Rhesus Monkeys.

Authors:  Jeanette M Shultz; Henry Resnikoff; Viktorya Bondarenko; Valerie Joers; Andres Mejia; Heather Simmons; Marina E Emborg
Journal:  J Alzheimers Dis Parkinsonism       Date:  2016-11-03

Review 6.  A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson's disease and potential molecular targets.

Authors:  Chenere P Ramsey; Malú G Tansey
Journal:  Exp Neurol       Date:  2013-05-28       Impact factor: 5.330

7.  Evaluation of the Neuroprotective Effect of Microglial Depletion by CSF-1R Inhibition in a Parkinson's Animal Model.

Authors:  Se Jong Oh; Heesu Ahn; Ki-Hye Jung; Sang Jin Han; Kyung Rok Nam; Kyung Jun Kang; Ji-Ae Park; Kyo Chul Lee; Yong Jin Lee; Jae Yong Choi
Journal:  Mol Imaging Biol       Date:  2020-08       Impact factor: 3.488

8.  Dicer expression is essential for adult midbrain dopaminergic neuron maintenance and survival.

Authors:  Xueyan Pang; Eric M Hogan; Alison Casserly; Guangping Gao; Paul D Gardner; Andrew R Tapper
Journal:  Mol Cell Neurosci       Date:  2013-10-31       Impact factor: 4.314

9.  Neuroprotective and anti-inflammatory effects of a therapy combining agonists of nicotinic α7 and σ1 receptors in a rat model of Parkinson's disease.

Authors:  Steven Vetel; Laura Foucault-Fruchard; Claire Tronel; Frédéric Buron; Jackie Vergote; Sylvie Bodard; Sylvain Routier; Sophie Sérrière; Sylvie Chalon
Journal:  Neural Regen Res       Date:  2021-06       Impact factor: 5.135

10.  Assessment of the Protection of Dopaminergic Neurons by an α7 Nicotinic Receptor Agonist, PHA 543613 Using [(18)F]LBT-999 in a Parkinson's Disease Rat Model.

Authors:  Sophie Sérrière; Aurélie Doméné; Johnny Vercouillie; Céline Mothes; Sylvie Bodard; Nuno Rodrigues; Denis Guilloteau; Sylvain Routier; Guylène Page; Sylvie Chalon
Journal:  Front Med (Lausanne)       Date:  2015-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.